Skye Bioscience Inc (SKYE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2014 | 07-2014 | 06-2014 | 04-2014 | 03-2014 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,025 | 39 | N/A | 50 | N/A |
| Receivables | N/A | 27 | N/A | 35 | N/A |
| Other current assets | 0 | 13 | 0 | 3 | 0 |
| TOTAL | $1,105 | $79 | $N/A | $88 | $N/A |
| Non-Current Assets | |||||
| PPE Net | 12 | 85 | N/A | 35 | N/A |
| Other Non-Current Assets | 9 | 4 | 0 | 0 | 0 |
| TOTAL | $21 | $89 | $N/A | $35 | $N/A |
| Total Assets | $1,126 | $168 | $N/A | $123 | $N/A |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 0 | 6 | 0 | 14 | 0 |
| Accrued Expenses | 350 | N/A | N/A | N/A | N/A |
| TOTAL | $350 | $44 | $N/A | $49 | $N/A |
| Non-Current Liabilities | |||||
| Long Term Debt | N/A | 43 | N/A | N/A | N/A |
| TOTAL | $N/A | $43 | $N/A | $N/A | $N/A |
| Total Liabilities | $350 | $87 | $N/A | $49 | $N/A |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 64 | 14 | N/A | 14 | N/A |
| Common Shares | 1,801 | 4 | N/A | 4 | N/A |
| Retained earnings | -1,215 | -6 | N/A | -13 | N/A |
| Other shareholders' equity | 190 | 0 | 0 | 0 | 0 |
| TOTAL | $776 | $81 | $N/A | $73 | $N/A |
| Total Liabilities And Equity | $1,126 | $168 | $0 | $123 | $0 |